替格瑞洛转换为氯吡格雷的药效学:SWAP-4研究
SWAP-4研究为前瞻性随机开放标签研究,纳入80例维持阿司匹林和氯吡格雷治疗的患者,经替格瑞洛7天导入后随机分4组比较不同转换策略的药效学。结果显示替格瑞洛维持治疗血小板反应性最低;降阶至氯吡格雷时血小板反应性升高,负荷剂量可减轻但不受给药时机影响。
要点
- 替格瑞洛降阶至氯吡格雷后血小板反应性升高,24小时即可出现。
- 氯吡格雷负荷剂量可减轻降阶后血小板反应性升高,与给药时机无关。
- 替格瑞洛维持治疗在各时间点血小板反应性均低于任何氯吡格雷方案。
核心结论
- 从替格瑞洛降阶至氯吡格雷与血小板反应性升高相关,负荷剂量可减轻但不受给药时机影响。
研究设计与样本
- 前瞻性随机开放标签研究,纳入80例维持阿司匹林81 mg/d和氯吡格雷75 mg/d的患者,经替格瑞洛180 mg负荷后90 mg每日两次7天导入,随机分4组。
主要发现
- 替格瑞洛90 mg每日两次在所有检测和时间点血小板反应性均低于任何氯吡格雷方案。
- C-600 mg-24h组与C-75 mg-24h组P2Y12反应单位相似(P=0.29),48小时主要终点最小均数差-6.9(95%CI -38.1至24.3;P=0.66)。
- C-600 mg-12h组P2Y12反应单位低于C-75 mg-24h组(P=0.024)。
- 最大血小板聚集C-600 mg-24h组(P=0.041)和C-600 mg-12h组(P=0.028)均低于C-75 mg-24h组。
- C-75 mg-24h组血小板反应性24小时即较基线升高,48和72小时达统计学显著并持续至10天。
临床怎么用
- 替格瑞洛降阶至氯吡格雷时可考虑使用氯吡格雷负荷剂量以减轻血小板反应性升高,给药时机在替格瑞洛末次维持剂量后12或24小时均可。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Switching between different classes of P2Y12 inhibitors, including de-escalation from ticagrelor to clopidogrel, commonly occurs in clinical practice. However, the pharmacodynamic profiles of this strategy have been poorly explored. METHODS: This was a prospective, randomized, open-label study conducted in patients on maintenance dosing (MD) of aspirin (81 mg/d) and clopidogrel (75 mg/d). After a 7-day run-in with ticagrelor (180 mg loading dose [LD] followed by 90 mg twice daily MD), patients (n=80) were randomized into 1 of 4 groups: group A, clopidogrel 600 mg LD 24 hours after the last MD of ticagrelor (C-600 mg-24h); group B, clopidogrel 600 mg LD 12 hours after the last MD of ticagrelor (C-600 mg-12h); group C, clopidogrel 75 mg/d MD 24 hours after the last MD of ticagrelor (C-75 mg-24h); and group D, ticagrelor 90 mg twice daily MD (T-90 mg twice daily). MD of the randomized treatment was maintained for 10±3 days. Pharmacodynamic assessments were performed at baseline, after run-in, and at 2, 24, 48, and 72 hours and 10 days with P2Y12 reaction units by VerifyNow; platelet reactivity index was assessed by vasodilator-stimulated phosphoprotein; and maximal platelet aggregation was determined by light transmittance aggregometry. RESULTS: T-90 mg twice daily led to lower platelet reactivity than any clopidogrel regimen using all assays at all time points. P2Y12 reaction unit levels were similar between the C-600 mg-24h (group A) and the C-75 mg-24h (group C) (P=0.29), including at 48 hours (primary end point; least mean difference, -6.9; 95% confidence interval, -38.1 to 24.3; P=0.66). P2Y12 reaction unit levels were lower with C-600 mg-12h (group B) than with C-75 mg-24h (group C; P=0.024). Maximal platelet aggregation over time was lower with both C-600 mg-24h (group A; P=0.041) and C-600 mg-12h (group B; P=0.028) compared with C-75 mg-24h (group C). Platelet reactivity index profiles paralleled those observed with P2Y12 reaction units. There were no pharmacodynamic differences for all tests between C-600 mg-24h (group A) and C-600 mg-12h (group B). In group C (C-75 mg-24h), platelet reactivity increased compared with baseline as early as 24 hours, reaching statistical significance at 48 and 72 hours and up to 10 days. These pharmacodynamic findings were delayed and blunted in magnitude with the administration of an LD, regardless of the timing of administration. CONCLUSIONS: De-escalation from ticagrelor to clopidogrel therapy is associated with an increase in platelet reactivity. The use of an LD before the initiation of an MD regimen of clopidogrel mitigates these observations, although this is not affected by the timing of its administration after ticagrelor discontinuation. CLINICAL TRIAL REGISTRATION: URL: https://www.clinicaltrials.gov. Unique identifier: NCT02287909.
引用
- Franchi F, Rollini F, Rivas Rios J, et al. Pharmacodynamic Effects of Switching From Ticagrelor to Clopidogrel in Patients With Coronary Artery Disease: Results of the SWAP-4 Study. Circulation. 2018. PMID: 29526833. doi:10.1161/CIRCULATIONAHA.118.033983
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。